PF-04965842

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial
Pharmaceutical Business Review
Thu, 05/16/19 - 10:55 am
Pfizer
clinical trials
PF-04965842
atopic dermatitis